Lebrikizumab in the treatment of asthma (Q38830570)

6 September 2017

title

Lebrikizumab in the treatment of asthma (English)

1 reference

6 September 2017

1 reference

Nicola A Hanania

1 reference

6 September 2017

Stephen Bujarski

1 reference

6 September 2017

Amit D Parulekar

series ordinal

1 reference

6 September 2017

language of work or name

English

0 references

publication date

10 May 2016

1 reference

Expert Opinion on Biological Therapy

6 September 2017

published in

1 reference

The global burden of asthma: executive summary of the GINA Dissemination Committee report

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Asthma phenotypes and endotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Asthma phenotypes: the evolution from clinical to molecular approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Severe asthma: from characteristics to phenotypes to endotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Monoclonal antibodies for the treatment of refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Future biologic therapies in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

New treatments for severe treatment-resistant asthma: targeting the right patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Which biomarkers are effective for identifying Th2-driven inflammation in asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

21 January 2018

Adult asthma biomarkers

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Group 2 innate lymphoid cells in the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Role of interleukin-13 in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Biologic targeted therapy in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Tailored therapy for severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

An update on biologic-based therapy in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

IL-4 and IL-13 signaling in allergic airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Periostin, a novel biomarker of TH2-driven asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Requirement for IL-13 independently of IL-4 in experimental asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Increased sputum and bronchial biopsy IL-13 expression in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Lebrikizumab in the personalized management of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

Roles of Periostin in Respiratory Disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2016.1182152

10.1080/14712598.2016.1182152

21 January 2018

Identifiers

DOI

0 references

1 reference